Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 73, Issue 10, 2014, Pages 1906-1908

  Lehane, P B ^a   Lacey, S ^a   Hessey, E W ^a   Jahreis, A ^b  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DAS28; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; AGED; ARTHRITIS, RHEUMATOID; DRUG INTERACTION; META ANALYSIS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84906988138     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205474     Document Type: Letter

References (10)

1. De Vera MA, Choi H, Abrahamowicz M, et al. Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken) 2012;64:809-16.
2. Janas E, Priest R, Wilde JI, et al. Rituxan (anti-CD20 antibody) induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005;139:439-46.
3. Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008;5:e64.
4. Arts EE, Jansen TL, Den Broeder A, et al. Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2011;70:877-8.
5. Das S, Fernandez Matilla M, Dass S, et al. Statins do not influence clinical response and B cell depleation after rituximab treatment in rheumatoid arthritis. Ann Rheum Dis 2013;72:463-4.
6. Mazilu D, Gudu T, Ionescu R, et al. Statins do not influence long-term rituximab clinical efficacy in rheumatoid arthritis patients. BioMed Res Int 2014;2014:689426.
7. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum 2006;54:1390-400.
8. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:2793-806.
9. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (SERENE). Ann Rheum Dis 2010;69:1629-35.
10. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46.